| ￥3600 | |
| Z03917-100 | |
|
|
|
|
|
|
|
|
|
| Species | Canine | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 47.6 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 75-80 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4 . | ||||
| Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
GUCY2C/Guanylyl cyclase C, His, Canineon Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
The purity of GUCY2C/Guanylyl cyclase C, His, Canine is greater than 95% as determined by SEC-HPLC. »
| Target Background | Guanylyl cyclase C (GUCY2C) has canonical centrality in defense of key intestinal homeostatic mechanisms, encompassing fluid and electrolyte balance, epithelial dynamics, antitumorigenesis, and intestinal barrier function. GUCY2C may represent a new target for anti-obesity pharmacotherapy. |
| Synonyms | Guanylyl cyclase C; GC-C; STAR; GUCY2C; GUC2C; STA receptor; DIAR6; EC 4.6.1; GCC; GUC2CEC 4.6.1.2; MUCIL |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
